11C-methionine PET for grading and prognostication in gliomas: A comparison study with 18F-FDG PET and contrast enhancement on MRI

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1709-1715

  Tarun Singhal, ^a,b   Tanjore K Narayanan, ^b   Martin P Jacobs, ^b   Chandrashekhar Bal, ^b   Mantil, Joseph C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Fluorodeoxyglucose; Gliomas; Methionine; MRI; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; CARBON-11 METHIONINE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; METHIONINE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN CORTEX; CANCER GRADING; CANCER SURVIVAL; CHILD; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; COMPARATIVE STUDY; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

ADULT; CHILD; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; METHIONINE; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84868333386     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102533     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts and Figures 2008. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ 2008cafffinalsecuredpdf.pdf. Accessed October 2, 2012.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
3. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
4. Stupp R, Janzer RC, Hegi ME, et al. Prognostic factors for low-grade gliomas. Semin Oncol. 2003;30:23-28.
5. Phelps ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661-681.
6. Hillner BE, Siegel BA, Liu BA, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry. J Clin Oncol. 2008;26:2155-2161.
7. Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med. 2008;38:240-250.
8. 18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
9. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
10. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
11. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
12. Narayanan TK, Said S, Mukherjee J, et al. A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol. 2002;4:147-156.
13. Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol. 1984;119:29-34.
14. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol. 2005;15:254-266.
15. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol. 1993;20:895-899.
16. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
17. Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238-253.
18. 11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR. 2006;27:1432-1437.
19. 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien). 1990;104:8-12.
20. 11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103:498-507.
21. Sasaki M, Kuwabara Y, Yoshida T, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25:1261-1269.
22. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699.
23. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785.
24. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-182.
25. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-2606.
26. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144:850-855.